福山達也 Summary：要約
Cancer is all too common in adult animals and is especially prevalent in senior pets. Diagnosing, staging, and treating cancer in dogs and cats and establishing a collaborative local or virtual relationship with veterinary oncologists for patient referrals and consultations are essential offerings in most full-service veterinary practices. Identifying the tumor type and stage are vital when selecting treatment and supporting clients as they weigh their options. Chemotherapy, surgery, immunotherapy, adjunctive treatments, and RT may be used alone or in combination depending on patient needs and client preferences. Therapeutic response must be assessed in the context of whether the original therapy was intended as cure or palliation. Managing quality of life in veterinary patients is especially meaningful for everyone involved and includes anticipating and preventing or minimizing discomfort and cancer treatment side effects, providing regular patient follow-up assessments, and maintaining transparent, relationship-focused communication with clients.
がんは成獣の動物では非常に一般的であり、特に高齢の愛犬・愛猫において高い頻度で認められる。犬および猫のがんを診断し、病期分類（ステージング）を行い、治療を実施すること、さらに患者紹介やコンサルテーションのために腫瘍専門医と地域またはオンラインで協力関係を構築することは、多くの総合動物病院において重要な診療サービスである。
治療方針を決定し、ペットオーナーが治療選択肢を検討する際に適切に支援するためには、腫瘍の種類と病期を正確に把握することが極めて重要である。化学療法、外科手術、免疫療法、補助療法、および放射線治療（RT）は、患者の状態やペットオーナーの希望に応じて単独または併用で実施される。
治療効果の評価は、その治療が当初「根治」を目的として行われたのか、それとも「緩和」を目的として行われたのかという文脈の中で判断する必要がある。
また、獣医腫瘍患者における生活の質（QOL）の管理は、関係するすべての人にとって非常に重要である。これには、不快感やがん治療による副作用を予測し予防する、あるいは最小限に抑えること、定期的な患者フォローアップ評価を行うこと、そしてペットオーナーとの透明性が高く信頼関係を重視したコミュニケーションを維持することが含まれる。
REFERENCES：文献
1. Withrow SJ, Vail DM, Page RL. Withrow and MacEwen’s Small Animal Clinical Oncology. 5th ed. Saunders; 2013.
2. Chon E, Hendricks W, White M, Rodrigues L, Haworth D, Post G. Precision medicine in veterinary science. Vet Clin North Am Small Anim Pract 2024;54(3):501–21.
3. Breit MN, Kisseberth WC, Bear MD, et al. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. BMC Vet Res 2014;10:160.
4. Cawley JR, Wright ZM, Meleo K, et al. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. J Vet Intern Med 2020;34(2):882–9.
5. London CA, Bernabe LF, Barnard S, et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One 2014;9(2):e87585.
6. Saba CF, Clifford C, Burgess K, et al. Rabacfosadine for naive canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Vet Comp Oncol 2020;18(4):763–9.
7. Saba CF, Vickery KR, Clifford CA, et al. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol 2018;16(1):E76–E82.
8. Sadowski AR, Gardner HL, Borgatti A, et al. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 2018;14(1):250.
9. Thamm DH, Vail DM, Post GS, et al. Alternating rabacfosadine/doxorubicin: efficacy and tolerability in naive canine multicentric lymphoma. J Vet Intern Med 2017;31(3):872–8.
10. Vlodaver EM, Keating MK, Bidot WA, et al. Efficacy of verdinexor for the treatment of naive canine epitheliotropic cutaneous T-cell lymphoma: An open-label pilot study. Vet Dermatol 2024;35(5):536–46.
11. Weishaar KM, Wright ZM, Rosenberg MP, et al. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma. J Vet Intern Med 2022;36(1):215–26.
12. Thamm DH, Vail DM, Kurzman ID, et al. GS-9219/VDC-1101–a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. BMC Vet Res 2014;10:30.
13. U.S. Food and Drug Administration. FDA conditionally approves first oral tablet to treat chemotherapy-induced diarrhea in dogs. December
21, 2021. Fda.gov. Available at https://www.fda.gov/news-events/ press-announcements/fda-conditionally-approves-first-oral-tablet-treatchemotherapy- induced-diarrhea-dogs. Accessed July 23, 2025.
14. Gilvetmab [package insert]. Rahway, New Jersey: Merck Animal Health. Available at https://merckusa.cvpservice.com/product/basic/view/1047586. Accessed July 23, 2025.
15. Cockery JR, Leifer CA. Racing CARs to veterinary immuno-oncology. Front Vet Sci 2023:10(2):1130182.
16. Xia YY, Chi KH, Liao AT, et al. Limited clinical efficacy with potential adverse events in a pilot study of autologous adoptive cell therapy for canine oral malignant melanoma. Vet Sci 2024;11(4):150.
17. McCafferty C. USDA approves new canine cancer therapy. DVM360. March 19, 2025. Available at https://www.dvm360.com/view/usda-approvesnew- canine-cancer-therapy. Accessed July 23, 2025.
18. De Ridder TR, Campbell JE, Burke-Schwarz C, et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). J Vet InternMed 2021;35(1):415–29.
19. Jones PD, Campbell JE, Brown G, et al. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. J Vet Intern Med 2021;35(1):451–5.
20. Reddell P, De Ridder TR, Morton JM, et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. J Vet Intern Med 2021; 35(1):430–41.
21. de Castro Cunha RM, Lavalle GE, Nunes FC, et al. Canine squamous cell carcinoma: Electrochemotherapy association with surgery and correlation with overall survival. Vet Comp Oncol 2023;21(2):240–54.
22. Dos Anjos DS, Bueno C, Magalh~aes LF, et al. Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma. Sci Rep 2019;9(1):15819.
23. Moretti G, Dentini A, Beccati F, et al. Palliative repeated electroporations of oral tumors in dogs: A case series. Front Vet Sci 2022;9:1004811.
24. Ramos SC, Dias-Pereira P, Lu ıs AL, et al. Electrochemotherapy in dogs and cats-A review. Vet Comp Oncol 2024;22(3):311–21.
25. Santos Dos Anjos D, Rossi YA, Sierra OR, et al. Outcome following curative-intent electrochemotherapy for extramedullary plasmacytoma in dogs – case reports. Top Companion Anim Med 2020;40:100441.
26. Tellado M, Mir LM, Maglietti F. Veterinary guidelines for electrochemotherapy of superficial tumors. Front Vet Sci 2022;9:868989.
27. Thalheim L, Williams LE, Borst LB, et al. Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. J Vet Intern Med 2013;27:1509–16.
28. Pun JKH. An integrated review of the role of communication in veterinary clinical practice. BMC Vet Res 2020;16(1):394.
29. Englar R. Recasting the gold standard – part I of II: delineating healthcare options across a continuum of care. J Feline Med Surg 2023;25(12): 1098612X231209855.
30. Carson CA. Nonverbal communication in veterinary practice. Vet Clin North Am Small Anim Pract 2007;37(1):49–63.
31. Englar R. Recasting the gold standard – part II of II: communicating healthcare options along a continuum of care. J Feline Med Surg 2023; 25(12):1098612X231215639.
32. Gaspar TB, Henriques J, Marconato L, et al. The use of low-dose metronomic chemotherapy in dogs—Insight into a modern cancer field. Vet Comp Oncol 2018;16:2–11.
33. Biller B. Metronomic chemotherapy in veterinary patients with cancer: Rethinking the targets and strategies of chemotherapy. Vet Clin North Am Small Anim Pract 2014;44(5):817–29.
34. Burton JH, Mitchell L, Thamm DH, et al. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. J Vet InternMed 2011;25(4):920–6.
35. Lana S, U’ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21(4):764–9.
36. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008;22(6): 1373–9.
37. Tripp CD, Fidel J, Anderson CL, et al. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 2011; 25(2):278–84.
38. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423–36.
39. Mitchell L, Thamm DH, Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet InternMed 2012;26(2):355–62.
40. Lew FH, McQuown B, Borrego J, Cunningham S, Burgess KE. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Vet Comp Oncol 2019;17(4):465–71.
41. Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med 2012;26(1):135–41.
42. London CA, Gardner HL, Mathie T, et al. Impact of toceranib/ piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi-institutional study. PLoS One 2015;29:10(4): e0124889.
43. Chon E, McCartan L, Kubicek LN, et al. Safety evaluation of combination toceranib phosphate (PalladiaVR ) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Vet Comp Oncol 2012;10(3):184–93.
44. Pellin MA, Wouda RM, Robinson K, et al. Safety evaluation of combination doxorubicin and toceranib phosphate (PalladiaVR ) in tumour bearing dogs: a phase I dose-finding study. Vet Comp Oncol 2017;15(3): 919–31.
45. Burton JH, Venable RO, Vail DM, et al. Pulse-administered toceranib phosphate plus lomustine for treatment of unresectable mast cell tumors in dogs. J Vet InternMed 2015;29(4):1098–104.
46. Pan X, Tsimbas K, Kurzman ID, et al. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(VR) ) in tumour-bearing dogs: a phase I dose-finding study. Vet Comp Oncol 2016;14(2):202–9.
47. Bavcar S, de Vos J, Kessler M, et al. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. Vet J 2017;224:1–6.
48. Wouda RM, Hocker SE, Higginbotham ML. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study. Vet Comp Oncol 2018;16(1):E52– E60.
49. Robat C, London C, Bunting L, et al. Safety evaluation of combination vinblastine and toceranib phosphate (PalladiaVR ) in dogs: a phase I dosefinding study. Vet Comp Oncol 2012;10(3):174–83.
50. Olsen JA, Thomson M, O’Connell K, et al. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Vet Med Sci 2018;4(3):237–51.
51. Rippy SB, Gardner HL, Nguyen SM, et al. A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma. BMC Vet Res 2016;12(1):257.
52. Falck K, Gr€ohn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;1(8128):1250–1.
53. Hon CY, Teschke K, Shen H, et al. Antineoplastic drug contamination in the urine of Canadian healthcare workers. Int Arch Occup Environ Health 2015;88(7):933–41.
54. Roussel C, Witt KL, Shaw PB, et al. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat Res Rev Mutat Res 2019;781: 207–17.
55. Smerhovsky Z, Landa K, R€ossner M, et al. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect 2001;109(1):41–5.
56. Anderson RW, Puckett WH, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982;39:1881–7.
57. Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001;7:394–403.
58. Christensen J. Hazardous drugs: The hidden threat to veterinary nurses. Today’s Veterinary Nurse. Winter 2023; 46–55.
59. National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2024. December 2024. Available at https://www.cdc.gov/niosh/docs/2025-103/ default.html. Accessed November 18, 2025.
60. P erez Fidalgo JA, Garc ıa Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012;23(suppl 7):vii167–vii173.
61. Fournier Q, Serra JC, Handel I, et al. Impact of pretreatment neutrophil count on chemotherapy administration and toxicity in dogs with lymphoma treated with CHOP chemotherapy. J Vet Intern Med 2018;32(1): 384–93.
62. Chavalle T, Chamel G, Denoeux P, et al. Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs. Vet Comp Oncol 2022;20(2):393–403.
63. Shaffer K, Bach J, Chun R. Prospective study evaluating the incidence of bacteraemia and bacteruria in afebrile and febrile neutropaenic dogs undergoing chemotherapy. Vet Med Sci 2016;2(4):281–94.
64. Cunha SC dos S, Silva FB, Corgozinho KB, et al. Retrospective study of adverse events of chemotherapy in cats. Acta Sci Vet 2018;46(1).
65. Chretin JD, Rassnick KM, Shaw NA, et al. Prophylactic trimethoprimsulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: A double-blind, placebo-controlled study. J Vet Intern Med. 2007;21(1):141–148.
66. Gumash M, Martin OA, Lindley SES, Zhu X. Prophylactic antimicrobials for prevention of febrile neutropenia in tumour-bearing dogs treated with lomustine. Vet Comp Oncol 2025;23(1):30–6.
67. Bisson JL, Fournier Q, Johnston E, et al. Evaluation of a 0.753109/L absolute neutrophil count cut-off for antimicrobial prophylaxis in canine cancer chemotherapy patients. Vet Comp Oncol 2020;18(3):258–68.
68. Dunfield EM, Turek MM, Buhr KA, et al. A survey of stereotactic radiation therapy in veterinary medicine. Vet Radiol Ultrasound 2018;59: 786–95.
69. Burney D, Jones G, Byers C, et al. 2025 AAHA Referral Guidelines. J Am Anim Hosp Assoc 2025;61(2):28–45.
70. AVMA. Veterinary telehealth: The basics. 2024. Available at https://www. avma.org/resources-tools/animal-health-and-welfare/telehealth-telemedicineveterinary- practice/veterinary-telehealth-basics. Accessed May 21, 2025.
71. Simonsen A. States must lift restrictions on telemedicine: Veterinary telemedicine saves lives, alleviates suffering and preserves the human-animal bond. June 12, 2023. Humanepro.org. Available at https://humanepro. org/blog/blog-states-must-lift-restrictions-telemedicine. Accessed May 21, 2025.
72. ASPCA. Position Statement on Veterinary Telemedicine. 2024. Available at https://www.aspca.org/about-us/aspca-policy-and-position-statements/position-statement-veterinary-telemedicine. Accessed May 21, 2025.
73. VVCA. 2024 Industry Report: Embracing the Future of Veterinary Care: Virtual Care. February 21, 2024. Available at https://vvca.org/embracingthe-future-of-veterinary-care-virtual-care/. Accessed May 21, 2025.
74. Johannes CM, Musser ML. Anorexia and the cancer patient. Vet Clin North Am Small Anim Pract 2019;49(5):837–54.
75. Rathore M, Das N, Ghosh N, et al. Insights on discovery, efficacy, safety and clinical applications of ghrelin receptor agonist capromorelin in veterinary medicine. Vet Res Commun 2024;48(1):1–10.
76. Rhodes L, Zollers B, Wofford JA, et al. Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs. Vet Med Sci 2018;4(1):3–16.
77. Zollers B, Wofford JA, Heinen E, et al. A prospective, randomized, masked, placebo-controlled clinical study of capromorelin in dogs with reduced appetite. J Vet Intern Med 2016;30(6):1851–7.
78. Ellis C, Odunayo A, Tolbert MK. The use of metronidazole in acute diarrhea in dogs: a narrative review. Top Companion Anim Med 2023; 56-57:100824.
79. Holden R, Brennan M. Does metronidazole increase the speed of recovery in dogs with acute diarrhoea? Vet Rec 2021;188(1):33–4.
80. St€ubing H, Suchodolski JS, Reisinger A, et al. The effect of metronidazole versus a synbiotic on clinical course and core intestinal microbiota in dogs with acute diarrhea. Vet Sci 2024;11(5).
81. Jugan MC, Wouda RM, Higginbotham ML. Preliminary evaluation of probiotic effects on gastrointestinal signs in dogs with multicentric lymphoma undergoing multi-agent chemotherapy: A randomised, placebocontrolled study. Vet Rec Open 2021;8(1):e2.
82. Fournier Q, Serra JC, Williams C, et al. Chemotherapy-induced diarrhoea in dogs and its management with smectite: Results of a monocentric open-label randomized clinical trial. Vet Comp Oncol 2021;19(1):25–33.
83. Gildea E, North C, Walker K, et al. Use of bedinvetmab (LibrelaVR) for canine osteoarthritis in France, Germany, Italy, Spain, and the UK: Quantitative analysis of veterinarian satisfaction and real-world treatment patterns. Animals (Basel) 2024;14(15):2231.
84. Walters RR, Boucher JF, De Toni F. Pharmacokinetics and immunogenicity of frunevetmab in osteoarthritic cats following intravenous and subcutaneous administration. Front Vet Sci 2021;8:687448.
85. Clark TP, Linton DD, Freise KJ, et al. Multicentered masked placebocontrolled phase 2 clinical study of an extended duration transdermal buprenorphine solution for postoperative pain in cats. J Vet Pharmacol Ther 2022;45(S1)(suppl 1):S40–S51.
86. Clark TP, Linton DD, Freise KJ, et al. Multicentered masked placebocontrolled phase 3 clinical study of an extended duration transdermal buprenorphine solution for post-operative pain in cats. J Vet Pharmacol Ther 2022;45(S1)(suppl 1):S52–S66.
87. Clark TP, Linton DD, Freise KJ, et al. Margin of safety of extendedduration transdermal buprenorphine solution following multiple-dose administrations to cats. J Vet Pharmacol Ther 2022;45(S1)(suppl 1):S67–S84.
88. Di Cesare F, Negro V, Ravasio G, et al. Gabapentin: clinical use and pharmacokinetics in dogs, cats, and horses. Animals (Basel). 2023;13(12):2045.
89. Anthony RM, Amundson MD, Brejda J, et al. Acceptance of a novel, highly palatable, calorically dense, and nutritionally complete diet in dogs with benign and malignant tumors. Vet Sci 2023;10(2):148.
90. Stockman J, Fascetti AJ, Kass PH, et al. Evaluation of recipes of homeprepared maintenance diets for dogs. J Am Vet Med Assoc 2013;242(11): 1500–5.
91. Candellone A, Badino P, Girolami F, et al. Concomitant campylobacteriosis in a puppy and in its caregiver: A One Health perspective paradigm in human-pet relationship. Vet Sci 2023;10(4):244.
92. Davies RH, Lawes JR, Wales AD. Raw diets for dogs and cats: a review, with particular reference to microbiological hazards. J Small Anim Pract 2019;60(6):329–39.
93. Ribeiro-Almeida M, Mour~ao J, Magalh~aes M, et al. Raw meat-based diet for pets: a neglected source of human exposure to Salmonella and pathogenic Escherichia coli clones carrying mcr, Portugal, September 2019 to January 2020. Euro Surveill 2024;29(18):2300561.
94. Nguyen SM, Thamm DH, Vail DM, et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2015;13(3):176–83.